Answers are grounded in this paper and cite their sources.
Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.
No takes yet. Share an insight, caveat, or question.
Landovitz et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: